Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

PET/CT in prostate cancer: non-choline radiopharmaceuticals.

Castellucci P, Jadvar H.

Q J Nucl Med Mol Imaging. 2012 Aug;56(4):367-74.

2.

PET/CT and choline: diagnosis and staging.

Farsad M, Schwarzenböck S, Krause BJ.

Q J Nucl Med Mol Imaging. 2012 Aug;56(4):343-53.

PMID:
23013664
3.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
4.

Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline.

Giovacchini G, Breeuwsma AJ.

Q J Nucl Med Mol Imaging. 2012 Aug;56(4):354-66.

PMID:
23013665
5.

18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.

Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, Gentile G, Vagnoni V, Romagnoli D, Martorana G, Fanti S.

Clin Genitourin Cancer. 2014 Apr;12(2):106-10. doi: 10.1016/j.clgc.2013.08.002. Epub 2013 Oct 14.

PMID:
24135632
6.

Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.

Nanni C, Schiavina R, Boschi S, Ambrosini V, Pettinato C, Brunocilla E, Martorana G, Fanti S.

Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S11-7. doi: 10.1007/s00259-013-2373-3. Epub 2013 Apr 17.

PMID:
23591953
7.

[Tracers in oncology - preclinical and clinical evaluation].

Krause BJ, Schwarzenböck S, Schwaiger M.

Nuklearmedizin. 2010;49 Suppl 1:S41-5. German.

PMID:
21152689
8.

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, Matarrese M, Matei DV, De Cobelli F, Del Maschio A, Rocco F, Rigatti P, Fazio F.

J Urol. 2003 Apr;169(4):1337-40.

PMID:
12629355
9.

18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.

Brogsitter C, Zöphel K, Kotzerke J.

Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S18-27. doi: 10.1007/s00259-013-2358-2. Epub 2013 Apr 12. Review.

PMID:
23579863
10.

[11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma.

Reske SN, Moritz S, Kull T.

Q J Nucl Med Mol Imaging. 2012 Oct;56(5):430-9.

PMID:
23069922
11.

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Jadvar H.

J Nucl Med. 2011 Jan;52(1):81-9. doi: 10.2967/jnumed.110.077941. Epub 2010 Dec 13. Review.

12.

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R.

BJU Int. 2007 Jun;99(6):1415-20. Epub 2007 Apr 8.

13.

Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.

Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S, Stenzl A.

BJU Int. 2008 Aug;102(4):446-51. doi: 10.1111/j.1464-410X.2008.07592.x. Epub 2008 Apr 11.

14.

Recent developments in urologic oncology: positron emission tomography molecular imaging.

Bouchelouche K, Oehr P.

Curr Opin Oncol. 2008 May;20(3):321-6. doi: 10.1097/CCO.0b013e3282f8b02b. Review.

PMID:
18391633
15.

[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.

Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S.

BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x. Epub 2012 Apr 23.

16.

Choline PET/CT for prostate cancer: main clinical applications.

Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S.

Eur J Radiol. 2011 Nov;80(2):e50-6. doi: 10.1016/j.ejrad.2010.07.023. Epub 2010 Aug 25. Review.

PMID:
20800404
17.

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE.

BJU Int. 2007 Oct;100(4):786-93.

18.

Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.

Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM.

J Nucl Med. 2002 Jan;43(1):46-55.

19.

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ.

Eur Urol. 2003 Jul;44(1):32-8; discussion 38-9.

PMID:
12814672
20.

Non-FDG PET in the practice of oncology.

Caroli P, Nanni C, Rubello D, Alavi A, Fanti S.

Indian J Cancer. 2010 Apr-Jun;47(2):120-5. doi: 10.4103/0019-509X.62998. Review.

Items per page

Supplemental Content

Write to the Help Desk